{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=TaiMed+Biologics+Inc.",
    "query": {
      "sponsor": "TaiMed Biologics Inc."
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-06T01:42:00.184Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03913195",
      "title": "Study of the Safety of Trogarzo™ Administered as an Undiluted \"IV Push\" or an Intramuscular Injection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV-1-infection"
      ],
      "interventions": [
        {
          "name": "ibalizumab-uiyk",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "TaiMed Biologics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2019-05-30",
      "completion_date": "2022-10-31",
      "has_results": true,
      "last_update_posted_date": "2025-10-20",
      "last_synced_at": "2026-10-06T01:42:00.184Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Fort Lauderdale, Florida • Orlando, Florida + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03913195"
    },
    {
      "nct_id": "NCT02707861",
      "title": "Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV"
      ],
      "interventions": [
        {
          "name": "ibalizumab",
          "type": "DRUG"
        },
        {
          "name": "Optimized Background Regimen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "TaiMed Biologics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 79,
      "start_date": "2016-03",
      "completion_date": "2018-11",
      "has_results": true,
      "last_update_posted_date": "2021-03-11",
      "last_synced_at": "2026-10-06T01:42:00.184Z",
      "location_count": 31,
      "location_summary": "Long Beach, California • Los Angeles, California • Palm Springs, California + 21 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02707861"
    },
    {
      "nct_id": "NCT07215468",
      "title": "HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV -1 Infection"
      ],
      "interventions": [
        {
          "name": "TMB-365",
          "type": "DRUG"
        },
        {
          "name": "TMB-380",
          "type": "DRUG"
        },
        {
          "name": "Baseline ART",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "TaiMed Biologics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 88,
      "start_date": "2025-12-16",
      "completion_date": "2027-05",
      "has_results": false,
      "last_update_posted_date": "2026-08-06",
      "last_synced_at": "2026-10-06T01:42:00.184Z",
      "location_count": 10,
      "location_summary": "San Francisco, California • Fort Lauderdale, Florida • Ft. Pierce, Florida + 7 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Ft. Pierce",
          "state": "Florida"
        },
        {
          "city": "Miami Gardens",
          "state": "Florida"
        },
        {
          "city": "Oakland Park",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07215468"
    },
    {
      "nct_id": "NCT05275998",
      "title": "TMB-365 and TMB-380 in Suppressed HIV-1 Infected Individuals",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HIV-1-infection"
      ],
      "interventions": [
        {
          "name": "TMB-365/TMB-380",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "TaiMed Biologics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 51,
      "start_date": "2022-07-05",
      "completion_date": "2024-11-20",
      "has_results": true,
      "last_update_posted_date": "2025-10-22",
      "last_synced_at": "2026-10-06T01:42:00.184Z",
      "location_count": 6,
      "location_summary": "San Francisco, California • Fort Lauderdale, Florida • Ft. Pierce, Florida + 3 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Ft. Pierce",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05275998"
    },
    {
      "nct_id": "NCT01292174",
      "title": "Safety Study of Ibalizumab Subcutaneous Injection in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prevention of Infection With HIV-1"
      ],
      "interventions": [
        {
          "name": "ibalizumab (biologic/MAb) for SC Injection or placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "TaiMed Biologics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 25,
      "start_date": "2011-02",
      "completion_date": "2012-09",
      "has_results": false,
      "last_update_posted_date": "2012-12-18",
      "last_synced_at": "2026-10-06T01:42:00.184Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Long Beach, California • San Francisco, California + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01292174"
    },
    {
      "nct_id": "NCT03110549",
      "title": "Study of the Safety, Tolerability and Pharmacokinetics of TMB-607 in HIV-Negative Volunteers",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "TMB-607",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "TaiMed Biologics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 9,
      "start_date": "2016-11-21",
      "completion_date": "2019-07-22",
      "has_results": false,
      "last_update_posted_date": "2020-05-12",
      "last_synced_at": "2026-10-06T01:42:00.184Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03110549"
    },
    {
      "nct_id": "NCT01056393",
      "title": "Investigator-Sponsored Protocol - Continued Use of Ibalizumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "ibalizumab 800mg Q2Weeks",
          "type": "DRUG"
        },
        {
          "name": "ibalizumab 2000mg Q4Weeks",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kaiser Permanente",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2009-11",
      "completion_date": "2016-12-15",
      "has_results": false,
      "last_update_posted_date": "2018-07-12",
      "last_synced_at": "2026-10-06T01:42:00.184Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01056393"
    },
    {
      "nct_id": "NCT02475629",
      "title": "Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV"
      ],
      "interventions": [
        {
          "name": "ibalizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Optimized Background Regimen (OBR)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "TaiMed Biologics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2015-08",
      "completion_date": "2016-12",
      "has_results": true,
      "last_update_posted_date": "2020-03-19",
      "last_synced_at": "2026-10-06T01:42:00.184Z",
      "location_count": 27,
      "location_summary": "Long Beach, California • Los Angeles, California • Palm Springs, California + 18 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02475629"
    },
    {
      "nct_id": "NCT04027387",
      "title": "Dose Escalation Safety Study of TMB-365 in HIV-1 Infected Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV-1-infection"
      ],
      "interventions": [
        {
          "name": "TMB-365",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "TaiMed Biologics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 24,
      "start_date": "2019-12-14",
      "completion_date": "2021-08-18",
      "has_results": false,
      "last_update_posted_date": "2021-10-06",
      "last_synced_at": "2026-10-06T01:42:00.184Z",
      "location_count": 5,
      "location_summary": "San Francisco, California • Ft. Pierce, Florida • Orlando, Florida + 2 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Ft. Pierce",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Jackson",
          "state": "Mississippi"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04027387"
    },
    {
      "nct_id": "NCT00784147",
      "title": "Dose-Response Study of Ibalizumab (Monoclonal Antibody) Plus Optimized Background Regimen in Patients With HIV-1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV"
      ],
      "interventions": [
        {
          "name": "Ibalizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "TaiMed Biologics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 113,
      "start_date": "2008-08",
      "completion_date": "2011-04",
      "has_results": true,
      "last_update_posted_date": "2014-05-05",
      "last_synced_at": "2026-10-06T01:42:00.184Z",
      "location_count": 28,
      "location_summary": "Beverly Hills, California • Long Beach, California • Los Angeles, California + 19 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00784147"
    }
  ]
}